GTBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GTBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, GT Biopharma's PE Ratio without NRI is 0.00. GT Biopharma's 5-Year EBITDA growth rate is 68.30%. Therefore, GT Biopharma's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for GT Biopharma's PEG Ratio or its related term are showing as below:
During the past 13 years, GT Biopharma's highest PEG Ratio was 13.78. The lowest was 0.00. And the median was 10.00.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for GT Biopharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GT Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
GT Biopharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, GT Biopharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, GT Biopharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where GT Biopharma's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
GT Biopharma's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 68.30 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
GT Biopharma (NAS:GTBP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of GT Biopharma's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Michael Martin Breen | director, officer: Exec. Chair. and Interim CEO | LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU |
Manu Ohri | officer: CFO & Secretary | 2355 MAIN STREET, SUITE 120, IRVINE CA 92614 |
Bruce Wendel | director | 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883 |
Gregory Berk | officer: Pres. of R&D, CMO | HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080 |
Shrotriya Rajesh C Md | director | 157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Alan Louis Urban | director | 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404 |
Gavin Choy | officer: Acting Chief Financial Officer | 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005 |
Steven W Weldon | director, officer: CFO | 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835 |
Shawn Cross | director, officer: Chief Executive Officer | 1825 K STREET SUITE 510, WASHINGTON DC 20006 |
Raymond W. Urbanski | officer: Chief Medical Officer | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Kathleen Clarence-smith | director, 10 percent owner, officer: CEO | 1623 31ST STREET NW, WASHINGTON DC 20007 |
Mark J Silverman | 10 percent owner | 224 22ND ST., SANTA MONICA CA 90402 |
Bristol Capital Llc | 10 percent owner | |
Bristol Investment Fund Ltd | 10 percent owner | 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-10-2022
By GuruFocusNews GuruFocusNews • 05-12-2022
By PurpleRose PurpleRose • 07-11-2022
By Marketwired • 11-06-2023
By PRNewswire PRNewswire • 02-24-2022
By PRNewswire PRNewswire • 03-28-2022
By GuruFocusNews GuruFocusNews • 04-11-2022
By Tiesvg Tiesvg • 12-30-2022
By Marketwired • 08-03-2023
By Stock market mentor Stock market mentor • 02-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.